tirzepatide onset Time to of AEs in patients receiving Early‐Onset Obesity and Tirzepatide Treatment:

Tirzepatide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Tiredness may occur when starting semaglutide treatment and during upward dose adjustments

IMDIAB Study Group

Drug repurposing, defined as researching new indications for already approved drugs, is gaining attention as a rapid and cost-efficient strategy for developing new treatments, the researchers wrote

We are dedicated to supporting our patients throughout their weight loss journey, helping them achieve and sustain their desired results with patience

Guidelines recommend GLP-1 agents with proven cardiovascular benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease